Biased Agonism Mediated by the Glucocorticoid Receptor

糖皮质激素受体介导的偏向激动

基本信息

  • 批准号:
    RGPIN-2018-04312
  • 负责人:
  • 金额:
    $ 2.33万
  • 依托单位:
  • 依托单位国家:
    加拿大
  • 项目类别:
    Discovery Grants Program - Individual
  • 财政年份:
    2018
  • 资助国家:
    加拿大
  • 起止时间:
    2018-01-01 至 2019-12-31
  • 项目状态:
    已结题

项目摘要

Background****Glucocorticoids are a family of naturally-occurring and synthetic agonists, which regulate the expression of genes controlling a wide variety of physiological functions including metabolism, development, inflammation and the immune system. These genomic effects are mediated by the glucocorticoid receptor (GR), a ligand-activated transcription factor, which is a member of the nuclear hormone receptor (NHR) superfamily.******Current concepts of GR-mediated gene expression assume that GR adopts the same, static conformation when bound by an activating ligand (i.e. agonist). Accordingly, the magnitude of gene expression changes is governed by the transcriptional competency of the ligand-receptor complex, which is determined by the innate chemical structure of the agonist. However, structural biologists have unequivocally established that GR can adopt multiple, interchangeable conformations, which are differentially stabilized in an agonist-dependent manner. Borrowing from the literature on 7-transmembrane spanning receptors, this plasticity may allow GR to interact, preferentially, with one gene promoter (or population of promoters) over another leading to distinct, agonist-directed programs of gene expression by a process called biased agonism.*******Hypothesis****The overall hypothesis is that distinct programs of GR-mediated gene expression can be generated in a given cell type that depend on the innate structure of an activating ligand and its ability to create unique conformations of GR. This changes the complement and stoichiometry of obligatory co-factors that bind to GR and, thereby, its ability to interact productively at certain gene promoters over others.*******Aims**** • To conduct a "proof-of-concept" study to establish GR-mediated gene expression bias;*** • To validate, quantify and analyse, using bioinformatics approaches, gene expression bias;*** • To explore in vitro the biological activity of biased GR agonists.******Anticipated Outcomes and Discovery Potential****This programme of research will apply biological, analytical and bioinformatics approaches, to establish a fundamental biological process of GR-mediated gene expression whereby distinct, transcriptional signatures are directed by the innate structure of an activating ligand. Many ligands have been identified with the potential to stabilise GR in distinct conformations and direct different patterns of gene expression through biased agonism. A ligand, by creating a unique, GR conformer, should be able to "program" a cell to preferentially express distinct populations of genes with attendant functional consequences. Establishing the principle of GR-mediated, biased agonism could be extrapolated to other NHRs, apply across species and be relevant to all biologists interested in the regulation of gene expression. ********
背景 * 糖皮质激素是天然存在的和合成的激动剂家族,其调节控制多种生理功能的基因的表达,包括代谢、发育、炎症和免疫系统。这些基因组效应由糖皮质激素受体(GR)介导,GR是一种配体激活的转录因子,是核激素受体(NHR)超家族的成员。GR介导的基因表达的当前概念假设GR在被活化配体(即激动剂)结合时采用相同的静态构象。因此,基因表达变化的幅度由配体-受体复合物的转录能力决定,这由激动剂的固有化学结构决定。然而,结构生物学家已经明确确定,GR可以采用多种可互换的构象,这些构象以激动剂依赖性方式差异稳定。借用7跨膜受体的文献,这种可塑性可能允许GR优先与一个基因启动子(或启动子群体)相互作用,而不是另一个基因启动子,从而通过一种称为偏向激动的过程产生不同的激动剂指导的基因表达程序。假设 * 总的假设是,GR介导的基因表达的不同程序可以在给定的细胞类型中产生,这取决于激活配体的先天结构及其产生GR独特构象的能力。这改变了与GR结合的强制性辅因子的互补性和化学计量,从而改变了其在某些基因启动子上与其他基因启动子有效相互作用的能力。目标 * ·进行“概念验证”研究,以确定GR介导的基因表达偏倚;* ·利用生物信息学方法验证、量化和分析基因表达偏差;* ·探索偏向性GR激动剂的体外生物活性。**预期成果和发现潜力 * 该研究计划将应用生物学,分析和生物信息学方法,建立GR介导的基因表达的基本生物过程,其中独特的转录特征由激活配体的先天结构指导。许多配体已被确定为具有稳定不同构象的GR的潜力,并通过偏性激动作用指导不同的基因表达模式。配体通过产生独特的GR构象异构体,应该能够“编程”细胞以优先表达具有伴随功能后果的不同基因群体。建立GR介导的有偏激动作用的原则可以外推到其他NHR,适用于跨物种,并与所有对基因表达调控感兴趣的生物学家相关。 ********

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Giembycz, Mark其他文献

Giembycz, Mark的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Giembycz, Mark', 18)}}的其他基金

Biased Agonism Mediated by the Glucocorticoid Receptor
糖皮质激素受体介导的偏向激动
  • 批准号:
    RGPIN-2018-04312
  • 财政年份:
    2022
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Discovery Grants Program - Individual
Biased Agonism Mediated by the Glucocorticoid Receptor
糖皮质激素受体介导的偏向激动
  • 批准号:
    RGPIN-2018-04312
  • 财政年份:
    2021
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Discovery Grants Program - Individual
Biased Agonism Mediated by the Glucocorticoid Receptor
糖皮质激素受体介导的偏向激动
  • 批准号:
    RGPIN-2018-04312
  • 财政年份:
    2020
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Discovery Grants Program - Individual
Biased Agonism Mediated by the Glucocorticoid Receptor
糖皮质激素受体介导的偏向激动
  • 批准号:
    RGPIN-2018-04312
  • 财政年份:
    2019
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Discovery Grants Program - Individual

相似海外基金

GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
GPR35:作为非酒精性脂肪肝疾病潜在治疗策略的作用和激动机制
  • 批准号:
    MR/X008827/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Research Grant
The role of biased agonism in the treatment of obesity
偏向激动在肥胖治疗中的作用
  • 批准号:
    MR/Y00132X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Fellowship
Mechanisms of weight loss due to dual GIP GLP-1 receptor agonism with tirzepatide compared to semaglutide
与索马鲁肽相比,替西帕肽双重 GIP GLP-1 受体激动导致的体重减轻机制
  • 批准号:
    479117
  • 财政年份:
    2023
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Operating Grants
Dissecting the Differential Impacts of Toll-like Receptor 9 Agonism on the Capacity of Human Natural Killer Cells to Mediate Target Cell Killing
剖析 Toll 样受体 9 激动剂对人类自然杀伤细胞介导靶细胞杀伤能力的不同影响
  • 批准号:
    10730451
  • 财政年份:
    2023
  • 资助金额:
    $ 2.33万
  • 项目类别:
Biased Agonism Mediated by the Glucocorticoid Receptor
糖皮质激素受体介导的偏向激动
  • 批准号:
    478650
  • 财政年份:
    2023
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Operating Grants
Understanding the molecular basis of partial agonism and G protein selectivity in GPCRs
了解 GPCR 中部分激动和 G 蛋白选择性的分子基础
  • 批准号:
    2890327
  • 财政年份:
    2023
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Studentship
Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer
不可逆电穿孔 (IRE) 联合 CD40 激动作为胰腺癌原位疫苗治疗
  • 批准号:
    10718057
  • 财政年份:
    2023
  • 资助金额:
    $ 2.33万
  • 项目类别:
Biased Agonism Mediated by the Glucocorticoid Receptor
糖皮质激素受体介导的偏向激动
  • 批准号:
    RGPIN-2018-04312
  • 财政年份:
    2022
  • 资助金额:
    $ 2.33万
  • 项目类别:
    Discovery Grants Program - Individual
Podocyte-specific Rap1 agonism for treatment of glomerular disease
足细胞特异性 Rap1 激动剂治疗肾小球疾病
  • 批准号:
    10441968
  • 财政年份:
    2022
  • 资助金额:
    $ 2.33万
  • 项目类别:
The effect of biased agonism at the Mu-Opioid receptor on drug seeking behavior
Mu-阿片受体的偏向激动对药物寻求行为的影响
  • 批准号:
    10590603
  • 财政年份:
    2022
  • 资助金额:
    $ 2.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了